News

Study shows circulating miRNA profiles change as myeloma progresses

A study, published recently in the Journal of Molecular Diagnostics, has shown that circulating microRNAs (miRNA) may be useful biomarkers for detecting the onset of myeloma and tracking its progression from earlier asymptomatic stages. miRNAs are small non-coding RNAs involved in the regulation of gene expression and interfere with the synthesis of specific proteins. In…

Details

Kyprolis® treatment combination recommended for use across Europe

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive recommendation for the use of Kyprolis (carfilzomib) in combination with Revlimid® (lenalidomide) and dexamethasone as a treatment for relapsed myeloma patients who have received at least one previous line of treatment. The recommendation was based on results of the…

Details

Kyprolis® undergoes FDA priority review for extended use in myeloma

Amgen has announced that the US Food and Drug Administration (FDA) has granted priority review for the extended use of Kyprolis (carfilzomib) as a treatment for myeloma patients. The company is looking to expand the current indication of Kyprolis in combination with Revlimid® (lenalidomide) and dexamethasone for relapsed myeloma patients who have received one to…

Details

Ixazomib receives FDA priority review for myeloma

Takeda, the Japanese pharmaceutical company, has announced that the US Food and Drug Administration (FDA) has granted Priority Review status to its New Drug Application for ixazomib as a treatment for relapsed and/or refractory myeloma patients. The application was based primarily on interim results from the pivotal Phase III TOURMALINE-MM1 trial comparing ixazomib in combination…

Details

Study demonstrates superiority of SKY92 genetic signature over other prognostic markers

A study, published recently in Blood, has found that the SKY92-signature (EMC92) for genetic subtyping of myeloma patients in combination with the International Staging System (ISS) classification is a stronger predictor for overall survival compared to other existing classifiers. The SKY92-signature developed by the Erasmus Medical Centre, Rotterdam, consisted of 92 genes directly or indirectly…

Details

Farydak® receives European approval as a treatment for myeloma

Novartis, the multi-national pharmaceutical company, has recently announced that the European Commission has approved Farydak (panobinostat) as a treatment for relapsed and/or refractory myeloma patients who have received at least two previous lines of treatment, including Velcade® (bortezomib) and an immunomodulatory drug. This is the first histone deacetylase (HDAC) inhibitor with epigenetic activity to be…

Details

Myeloma drugs removed from Cancer Drugs Fund

NHS England has announced that Imnovid® (pomalidomide) for relapsed and refractory myeloma patients and Revlimid® (lenalidomide) for treatment at first relapse will no longer be available via the Cancer Drugs Fund (CDF) following a recent reassessment of the cancer drugs being funded this way. This applies only to patients in England, which will take effect…

Details

Imnovid® approved for myeloma patients in Wales

The All Wales Medicines Strategy Group (AWMSG) has approved the use of Imnovid® (pomalidomide) for relapsed and/or refractory myeloma patients who have previously received both bortezomib and lenalidomide. The approval was based on trial data demonstrating that Imnovid, in combination with dexamethasone, significantly improved progression-free and overall survival compared to dexamethasone alone. Imnovid is also…

Details